Abstract | BACKGROUND: AIM: METHODS: RESULTS: Soluble syndecan-1 levels were significantly higher in inflammatory bowel disease patients compared to healthy controls (29.5 ± 13.4 vs. 21.1 ± 10.4 ng/ml, respectively, P = 0.03). Soluble syndecan-1 displayed a reliable ability to discriminate inflammatory bowel disease patients from healthy controls with a sensitivity of 95 %, specificity of 50 %, and positive predictive value of 83 %. Patients treated with anti-inflammatory medications demonstrated significantly lower soluble syndecan-1 levels compared to untreated patients (26.45 ± 9.75 vs. 38 ± 18.43 ng/ml, respectively, P = 0.008). CONCLUSIONS:
|
Authors | Doron Yablecovitch, Assaf Stein, Maytal Shabat-Simon, Timna Naftali, Gila Gabay, Ido Laish, Asaf Oren, Fred M Konikoff |
Journal | Digestive diseases and sciences
(Dig Dis Sci)
Vol. 60
Issue 8
Pg. 2419-26
(Aug 2015)
ISSN: 1573-2568 [Electronic] United States |
PMID | 25702042
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Cross-Sectional Studies
- Female
- Humans
- Inflammatory Bowel Diseases
(blood)
- Logistic Models
- Male
- Middle Aged
- Pilot Projects
- Solubility
- Syndecan-1
(blood)
|